Trial Profile
A phase 2 study of Apristor in combination with Fulvestrant in 2L therapy in advanced breast cancer patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2018
Price :
$35
*
At a glance
- Drugs Onapristone (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 28 Aug 2018 New trial record
- 08 Aug 2018 According to a Context Therapeutics media release, this study is planned to start in early 2019